BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.60, $0.39 better than the analyst estimate of $0.21. Revenue for the quarter came in at $596.4 million versus the consensus estimate of $571.33 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.